TOP TEN perturbations for 1039_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1039_s_at
Selected probe(set): 200989_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1039_s_at (200989_at) across 6672 perturbations tested by GENEVESTIGATOR:

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-3.4282236
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

multiple myeloma study 3 (primary) / MGUS study 1

Relative Expression (log2-ratio):-3.3434362
Number of Samples:5 / 3
Experimental multiple myeloma study 3 (primary)
Plasma cell (PC) samples from patients with primary multiple myeloma (MM).
Control MGUS study 1
Plasma cell (PC) samples from patients with monoclonal gammopathy of undetermined significance (MGUS).

HIF-1a depletion study 1 (siRNA) / deferoxamine study 5

Relative Expression (log2-ratio):-3.0216627
Number of Samples:3 / 3
Experimental HIF-1a depletion study 1 (siRNA)
siRNA against HIF-1a treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h).
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

HIF-2a depletion study 1 (hypoxia; AB81) / HIF-1a depletion study 2 (hypoxia; AB81)

Relative Expression (log2-ratio):2.986494
Number of Samples:3 / 3
Experimental HIF-2a depletion study 1 (hypoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-2a (Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (1% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.
Control HIF-1a depletion study 2 (hypoxia; AB81)
Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a (Hypoxia-inducible factor 1-alpha) 24 hours after treatment with hypoxia (1% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

B-CLL study 9 (CD19+; CD5+) / normal B-cell sample (CD19+)

Relative Expression (log2-ratio):-2.6668224
Number of Samples:172 / 20
Experimental B-CLL study 9 (CD19+; CD5+)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL). B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control normal B-cell sample (CD19+)
CD19+ B-cell samples from normal control subjects. B-cells were isolated from peripheral blood mononuclear cells.

Langerhans cell histiocytosis study 2 (multifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.6037436
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

Waldenström macroglobulinemia study 3 / multiple myeloma study 3 (primary)

Relative Expression (log2-ratio):2.5951633
Number of Samples:27 / 5
Experimental Waldenström macroglobulinemia study 3
Plasma cell (PC) samples from patients with Waldenströms macroglobulinemia (WM).
Control multiple myeloma study 3 (primary)
Plasma cell (PC) samples from patients with primary multiple myeloma (MM).

HIF-1a/HIF-2a depletion study 1 (normoxia; HK2) / control HK2 cell sample (normoxia)

Relative Expression (log2-ratio):-2.3734894
Number of Samples:3 / 6
Experimental HIF-1a/HIF-2a depletion study 1 (normoxia; HK2)
Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control control HK2 cell sample (normoxia)
Proximal tubule epithelial cell line HK-2 treated with normoxia (20% O2) for 24 hours. HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.

Langerhans cell histiocytosis study 2 (unifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):2.3357916
Number of Samples:8 / 10
Experimental Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

expO breast cancer study 1 (papillary carcinoma, NOS; primary) / expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)

Relative Expression (log2-ratio):-2.238904
Number of Samples:2 / 3
Experimental expO breast cancer study 1 (papillary carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with papillary carcinoma (NOS).
Control expO breast cancer study 1 (metaplastic carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with metaplastic carcinoma (NOS).